Objective
=========

Cardiovascular disease (CVD) is the leading cause of death in Mississippi; in 2013 the state's CVD death rate was 1.4 times the national rate ([@R1]). The benefits of aspirin use in CVD prevention have been documented ([@R2]--[@R4]). The Mississippi State Department of Health (MSDH) and the Centers for Disease Control and Prevention (CDC), through a cooperative agreement (Mississippi Delta Health Collaborative), are implementing interventions across the 18-county Mississippi Delta region. These interventions target the ABCS (aspirin for those eligible, blood pressure control, cholesterol management, and smoking cessation) of heart disease and stroke prevention. However, the prevalence of aspirin use among eligible Mississippians for primary and secondary CVD prevention as recommended by the US Preventive Services Task Force (USPSTF) ([@R5]) has not been assessed.

Methods
=======

The Behavioral Risk Factor Surveillance System (BRFSS) is a state-based, random-digit--dialed telephone survey of the noninstitutionalized US civilian population aged 18 years or older. BRFSS is conducted in all 50 states, the District of Columbia, and 3 US territories (Puerto Rico, Guam, and the US Virgin Islands) and has been approved by the human research review board at each state's department of health. Detailed information about BRFSS is available ([www.cdc.gov/brfss/](http://www.cdc.gov/brfss/)). Our analyses were restricted to men aged 45 to 79 years and women aged 55 to 79 years who responded to the 2013 Mississippi BRFSS. Guidelines for aspirin use were based on the 2009 USPSTF recommendations ([@R5]), not the recommendations issued in 2016 ([@R6]), because the 2009 recommendations were current when data were collected in 2013. We excluded respondents who self-reported a contraindication to aspirin use (n = 689) --- those who responded to the question "Do you have a problem or health condition that makes taking aspirin unsafe for you?" with either "yes, not stomach related" or "yes, stomach problems" ([@R7]). Men aged 45 to 79 and women aged 55 to 79 without CVD or with contraindications to aspirin use were considered eligible to use aspirin for the primary prevention of CVD, and women and men in the same age categories with a history of CVD but without contraindications were considered eligible for aspirin use for secondary prevention.

Cardiovascular disease
----------------------

CVD was defined as a yes response to at least one of the following questions: "Has a doctor, nurse, or other health professional ever told you that you had any of the following? 1) a heart attack, also called a myocardial infarction, 2) angina or coronary heart disease, 3) a stroke." Respondents who had never been told they had CVD were considered eligible for primary prevention, whereas those with a history of CVD were considered eligible for secondary prevention. Analyses were restricted to respondents who self-identified as black or white; these 2 racial groups accounted for 96.6% of the study population. This study was deemed exempt from approval by the MSDH institutional review board. Weighted prevalence and 95% confidence intervals (CIs) were calculated, and the χ^2^test was used to examine sociodemographic differences. SAS version 9.4 (SAS Institute Inc) was used to perform all statistical analyses; *P* values of less than .05 were considered significant.

Results
=======

More than two-thirds (68.0%; 95% CI, 65.2%--71.2%) of eligible adults were white. Most had health insurance, more than a third were obese (body mass index \[kg/m^2^\] ≥30.0), and 18.9% (95% CI, 16.3%--21.4%) of men and 17.8% (95% CI, 15.4%--20.2%) of women reported having CVD. Among those without CVD, 39.1% (95% CI, 35.4%--42.9%) of men and 45.9% (95% CI, 42.3%--49.4%) of women were taking aspirin for primary prevention.

The prevalence of aspirin use for primary prevention among men was significantly higher among those with health insurance (41.2%; 95% CI, 37.1%--45.4%; *P* = .02), those with diabetes (56.0%; 95% CI, 46.4%--65.6%; *P* = .002), and those in poor or fair health (47.5%; 95 CI, 39.0%--56.0%; *P* = 0.03) relative to their counterparts. We found significant differences by education levels (*P* = .02) for men. For women, the prevalence of aspirin use for primary prevention was significantly higher among those in fair or poor health (56.5%; 95% CI, 49.4%--63.6%; *P* = .003) and those with diabetes (60.6%; 95% CI, 53.0%--68.2%; *P* \< .001) than among their counterparts. We found significant differences among women by income level (*P* = .02) ([Table 1](#T1){ref-type="table"}).

###### Characteristics of Eligible Mississippi Adults[a](#T1FN1){ref-type="table-fn"} Taking Aspirin for the Primary Prevention of Cardiovascular Disease, Mississippi Behavioral Risk Factor Surveillance System, 2013

  Characteristic                      Men Aged 45--79 Years   Women Aged 55--79 Years                                                    
  ----------------------------------- ----------------------- ------------------------- -------- ------------------- ------------------- --------
  **Overall**                         133,052                 39.1 (35.4--42.9)                  107,814             45.9 (42.3--49.4)   
  **Race**                                                                                                                               
  Black                               36,082                  34.0 (27.0--41.1)         .08      35,237              48.5 (42.1--55.0)   .35
  White                               96,770                  41.7 (37.3--46.1)         72,421   44.8 (40.6--49.1)                       
  **Education**                                                                                                                          
  \<High school diploma               23,225                  30.4 (21.8--39.0)         .02      24,285              47.0 (37.4--56.6)   .31
  High school diploma or equivalent   41,391                  37.6 (31.3--43.9)         39,079   49.2 (43.2--55.2)                       
  \>High school diploma               68,435                  44.7 (39.4--50.1)         44,157   42.6 (38.0--47.2)                       
  **Annual household income, \$**                                                                                                        
  \<35,000                            58,244                  41.2 (35.1--47.3)         .57      54,993              48.8 (43.3--54.3)   .02
  ≥35,000                             64,604                  38.2 (33.0--43.4)         33,243   39.5 (34.1--45.0)                       
  No answer                           10,204                  34.6 (22.6--46.5)         19,638   51.1 (43.4--58.7)                       
  **Health insurance**                                                                                                                   
  Yes                                 115,576                 41.2 (37.1--45.4)         .02      95,911              47.6 (44.0--51.2)   .07
  No                                  17,441                  29.5 (20.8--38.1)         11,791   35.5 (23.5--47.5)                       
  **General health**                                                                                                                     
  Fair/poor                           34,164                  47.5 (39.0--56.0)         .03      37,690              56.5 (49.4--63.6)   .001
  Excellent/good                      98,888                  36.9 (32.7--41.1)         70,038   41.8 (37.9--45.7)                       
  **Current smoking**                                                                                                                    
  Yes                                 29,336                  36.0 (27.9--44.2)         .37      16,809              43.8 (33.6--54.0)   .66
  No                                  103,337                 40.3 (36.1--44.6)         90,155   46.2 (42.5--50.0)                       
  **Body mass index, kg/m^2^**                                                                                                           
  \<25.0                              21,686                  31.9 (24.2--39.6)         .12      30,108              45.7 (38.7--52.7)   .27
  25.0 to \<30.0                      56,059                  40.5 (34.6--46.4)         33,879   43.3 (37.1--49.5)                       
  ≥30.0                               53,892                  40.5 (34.6--46.4)         37,453   50.4 (44.5--56.2)                       
  **Diabetes**                                                                                                                           
  Yes                                 29,225                  56.0 (46.4--65.6)         .001     27,838              60.6 (53.0--68.2)   \<.001
  No                                  103,827                 36.1 (32.0--40.2)         79,977   42.3 (38.3--46.3)                       

Abbreviation: CI, confidence interval.

Respondents who had never been told by a physician or health care provider that they had a stroke, heart attack, or coronary heart disease.

Determined by using χ^2^ test.

Overall, of those with CVD, 85.9% (95% CI, 80.8%--91.0%) of men and 85.1% (95% CI, 79.8%--90.5%) of women were taking aspirin. Among men with CVD, the prevalence of aspirin use was significantly higher among white men (90.2%; 95% CI, 85.8%--94.6%) than among black men (76.0%; 95% CI, 63.1%--89.0%) (*P* = .01). Among women with CVD, aspirin use was significantly higher among those with diabetes (94.4%; 95% CI 89.4%--99.4%; *P* = .004) than among those without diabetes. We found significant differences by education level among women (*P* = .04) ([Table 2](#T2){ref-type="table"}).

###### Eligible Mississippi Adults[a](#T2FN1){ref-type="table-fn"} Taking Aspirin for the Secondary Prevention of Cardiovascular Disease, Mississippi Behavioral Risk Factor Surveillance System, 2013

  Characteristic                      Men Aged 45--79 Years   Women Aged 55--79 Years                                                     
  ----------------------------------- ----------------------- ------------------------- -------- -------------------- ------------------- ------
  **Overall**                         68,563                  85.9 (80.8--91.0)                  43,100               85.1 (79.8--90.5)   
  **Race**                                                                                                                                
  Black                               18,096                  76.0 (63.1--89.0)         .01      13,392               81.4 (72.3--90.5)   .36
  White                               50,331                  90.2 (85.8--94.6)         28,911   86.6 (79.8--93.4)                        
  **Education**                                                                                                                           
  \<High school diploma               22,776                  86.4 (76.9--95.9)         .79      12,223               76.2 (63.0--89.3)   .04
  High school diploma or equivalent   20,579                  88.0 (79.9--96.2)         15,597   88.6 (82.6--94.6)                        
  \>High school diploma               25,208                  83.8 (75.4--92.2)         14,972   89.8 (83.2--96.5)                        
  **Annual household income, \$**                                                                                                         
  \<35,000                            40,150                  85.4 (78.5--92.5)         .50      25,319               81.6 (73.9--89.2)   .13
  ≥35,000                             22,712                  89.0 (81.8--96.2)         6,081    86.9 (73.5--100.0)                       
  No answer                           5,701                   78.0 (58.1--97.8)         11,700   92.9 (87.3--98.5)                        
  **Health insurance**                                                                                                                    
  Yes                                 64,666                  85.9 (80.7--91.1)         .94      39,134               85.4 (79.8--91.0)   .72
  No                                  3,830                   85.1 (62.8--100.0)        3,792    82.0 (62.7--100.0)                       
  **General health**                                                                                                                      
  Fair/poor                           39,474                  86.5 (79.7--93.2)         .96      24,993               84.7 (77.7--91.6)   .85
  Excellent/good                      28,653                  86.7 (79.3--94.2)         18,107   85.8 (77.4--94.1)                        
  **Current smoking**                                                                                                                     
  Yes                                 18,993                  82.9 (72.0--93.9)         .49      8,398                76.8 (61.2--92.3)   .13
  No                                  49,569                  87.1 (81.5--92.7)         34,408   87.3 (82.2--92.5)                        
  **Body mass index, kg/m^2^**                                                                                                            
  \<25.0                              12,660                  82.8 (71.0--94.6)         .16      10,634               88.3 (81.0--95.7)   .40
  25.0 to \<30.0                      27,070                  93.2 (87.8--98.6)         13,946   87.1 (77.4--96.7)                        
  ≥30.0                               26,920                  85.0 (77.3--92.7)         15,791   80.2 (70.2--90.2)                        
  **Diabetes**                                                                                                                            
  Yes                                 27,073                  89.0 (81.9--96.0)         .33      17,976               94.4 (89.4--99.4)   .004
  No                                  41,489                  84.0 (77.1--90.8)         24,992   79.4 (71.6--87.3)                        

Abbreviation: CI, confidence interval.

Respondents who reported that a doctor or health care provider had previously told them that they had been diagnosed with a stroke, heart attack, or coronary heart disease.

Determined by using χ^2^ test.

Discussion
==========

In 2013, more than a third of eligible Mississippians without CVD were taking aspirin daily for primary prevention, while most (over 85%) of those with CVD were taking aspirin daily. This finding is consistent with results reported for other states ([@R8]). In addition, the overall high rate of aspirin use for secondary prevention among eligible Mississippi adults is similar to results reported for nationally representative samples ([@R9]). The ongoing collaborative efforts of MSDH and CDC to promote the ABCS of heart disease prevention in the Mississippi Delta region, which has a disproportionately high burden of CVD, must seek to increase the awareness and promotion of strategies that target those with less education, without health insurance, and without diabetes and those with good or excellent health who are eligible for primary prevention. Evidence-based practice and clinical management procedures following CVD events, aspirin-use counseling, and community-based interventions to promote the benefits of regular aspirin use among those eligible are needed to increase aspirin use ([@R9]), particularly among black adults with CVD. Future studies should further examine the disparities in aspirin use among eligible Mississippi adults.

These findings have potential limitations. First, the data are self-reported, which could lead to recall bias ([@R9]), and aspirin does not require a prescription for purchase. Second, because of the cross-sectional study design there could be temporality bias. Third, the questions used in BRFSS to define CVD might underestimate CVD in the population, because they do not refer to all types of CVD. Increased aspirin use could improve CVD risk prevention and reduction among eligible Mississippi adults. Our findings indicate that a significant proportion of eligible Mississippi adults could benefit from using aspirin to prevent CVD ([@R6]).
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